https://www.benzinga.com/general/biotech/24/11/41884773/astrazeneca-q3-earnings-preview-will-cancer-heart-drugs-fuel-continued-growth
AstraZeneca is set to report its third-quarter 2024 earnings Tuesday morning. The company's Q2 performance suggests strong growth driven by its oncology and cardiovascular portfolios.
Create an account or login to join the discussion